Skip to main content

Water Dispersible Fe3O4 Nanoparticles Carrying Doxorubicin for Cancer Therapy

Buy Article:

$105.00 plus tax (Refund Policy)

Water dispersible Fe3O4 nanoparticles (coated with Poly Vinyl Pyrolidone (PVP) and Poly oxy ethylene 25- propylene glycol stearate (POES)) and complexed with Doxorubicin has been prepared and characterized using X-ray diffraction (XRD), transmission electron microscopy (TEM) and vibrating sample magnetometer (VSM). The antitumor activity of these particles has been studied by targeting the complex to the tumor site, using an externally applied magnetic field, after oral administration of the magnetic nanoparticle-drug complexes. Our results reveal that the chemotherapy effect of Doxorubicin could be considerably enhanced by combination of the application of the drug-conjugated magnetic Fe3O4 nanoparticles, which are biocompatible and stable, and targeted drug delivery with a magnet. The present report provides the first evidence for the promising application of this novel approach with PVP coated Fe3O4 nanoparticles for cancer therapy using an in vivo murine model.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: 01 November 2009

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more